Related Experiment Video
Updated: Aug 29, 2025
08:08
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
16.4K
Mass Spectrometric-Based Proteomics for Biomarker Discovery in Osteosarcoma: Current Status and Future Direction
Nutnicha Sirikaew1,2, Dumnoensun Pruksakorn1,3, Parunya Chaiyawat1,3
1Musculoskeletal Science and Translational Research (MSTR) Center, Department of Orthopedics, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
International Journal of Molecular Sciences
|September 9, 2022
Summary
Osteosarcoma research needs new treatments and biomarkers. Proteomics using mass spectrometry (MS) can identify potential biomarkers for diagnosis and therapy, improving patient outcomes.
Area of Science:
- Oncology
- Biochemistry
- Proteomics
Background:
- Osteosarcoma patient outcomes have stagnated due to a lack of novel therapies and biomarkers.
- Proteomics offers a powerful approach to investigate protein expression in osteosarcoma.
Purpose of the Study:
- To review current proteomics studies in osteosarcoma.
- To identify potential protein biomarkers for diagnosis, prognosis, and treatment response.
- To discuss the future of mass spectrometry-based proteomics in osteosarcoma research.
Main Methods:
- Review of existing literature on osteosarcoma proteomics.
- Application of mass spectrometry (MS) for peptide quantification.
- Downstream pathway analysis of protein profiles.
Main Results:
- Proteomics enables the investigation of protein profiles from various sample types.
- Identified potential biomarkers for osteosarcoma diagnosis and prognosis.
- Highlighted candidate biomarkers for stratifying chemotherapy response.
Conclusions:
- Mass spectrometry-based proteomics is crucial for advancing osteosarcoma research.
- Further research can uncover promising therapeutic targets and improve clinical outcomes.
- Addressing challenges in proteomics will unlock opportunities for biomarker discovery.
